California - based start - up Ambrosia has claimed injection of so - called " young blood " - that is to say blood from younger donors - into older patients have improved biomarkers related to diabetes , Alzheimer ’s and heart disease , according to founder Jesse Karmazin . Of the almost 80 patients the firm has dealt with , 21 % have seen reduced levels of carcinoembryonic antigens , a protein which can indicate the presence of certain cancers , a 20 % drop in levels of amyloids , compatibility with Alzheimer 's , and average blood cholesterol levels down 10 % , according to colleagues . However , medical experts are sceptical of the results promised , with " controlled studies reviewed through established peer - review channels " needed , according to Dr. Tony Wyss - Coray , a professor of neurology at Stanford University .
California-based start-up Ambrosia has claimed transfusions of so-called "young blood" - that is to say blood from younger donors - into older patients have improved biomarkers related to cancer, Alzheimer’s and heart disease, according to founder Jesse Karmazin. Of the almost 80 customers the firm has worked with, 21% have seen reduced levels of carcinoembryonic antigens, a protein which can indicate the presence of certain cancers, a 20% drop in levels of amyloids, associated with Alzheimer's, and average blood cholesterol levels down 10%, according to Karmazin. However, medical experts are sceptical of the results promised, with "controlled studies reviewed through established peer-review channels" needed, according to Dr. Tony Wyss-Coray, a professor of neurology at Stanford University.